Ubaldo Visco Comandini

Medicine & Life Sciences

1. HIV 100%
2. HIV-1 99%
3. Hepacivirus 59%
4. Liver Transplantation 49%
5. Sofosbuvir 48%
6. Antiviral Agents 47%
7. Italy 43%
8. Hepatitis C 41%
9. Genotype 41%
10. Ribavirin 38%
11. RNA 37%
12. Mutation 32%
13. Compassionate Use Trials 29%
14. CD4 Lymphocyte Count 27%
15. Viremia 27%
16. Highly Active Antiretroviral Therapy 26%
17. Viral Load 26%
18. Therapeutics 26%
19. Infections 25%
20. HIV Infections 25%
21. Liver 24%
22. Drug Resistance 24%
23. Fibrosis 24%
24. SARS Virus 22%
25. Chronic Hepatitis C 21%
26. BMS-790052 21%
27. Virus Diseases 21%
28. Hepatitis B virus 20%
29. Enfuvirtide 20%
30. Quasispecies 19%
31. Pharmaceutical Preparations 18%
32. Hepatitis Delta Virus 18%
33. Acquired Immunodeficiency Syndrome 17%
34. Transplant Recipients 17%
35. DNA 16%
36. Pandemics 15%
37. Transplants 15%
38. High-Throughput Nucleotide Sequencing 13%
39. Interferons 13%
40. Reverse Transcriptase Inhibitors 13%
41. Chlamydophila pneumoniae 12%
42. T-Lymphocytes 12%
43. nef Genes 12%
44. Viruses 12%
45. Pneumonia 12%
46. Chronic Hepatitis 12%
47. Communicable Diseases 11%
48. Dialysis 11%
49. Human immunodeficiency virus 1 p16 protease 11%
50. Chemical and Drug Induced Liver Injury 10%